Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2024-02 · 22 (1) · 43-69
DOI: 10.6004/jnccn.2024.0007 ↗Kurz gefasst
Leitlinie in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2024-02. Verfasst von Neil P Shah und 32 weiteren Autor:innen. Beteiligte Einrichtung: 1UCSF Helen Diller Family Comprehensive Cancer Center. Hauptthemen laut MEDLINE: Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase. Die Arbeit wurde bisher 140-mal zitiert (Crossref) und nennt 297 Literaturangaben.
Abstract (Originalsprache)
Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome resulting from a reciprocal translocation between chromosomes 9 and 22 [t9;22] that gives rise to a BCR::ABL1 fusion gene. CML occurs in 3 different phases (chronic, accelerated, and blast phase) and is usually diagnosed in the chronic phase in developed countries. Tyrosine kinase inhibitor (TKI) therapy is a highly effective treatment option for patients with chronic phase–CML. The primary goal of TKI therapy in patients with chronic phase–CML is to prevent disease progression to accelerated phase–CML or blast phase–CML. Discontinuation of TKI therapy with careful monitoring is feasible in selected patients. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with chronic phase–CML.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- 1UCSF Helen Diller Family Comprehensive Cancer Center.
- 2O'Neal Comprehensive Cancer Center at UAB.
- 3Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
- 4University of Colorado Cancer Center.
- 5Mayo Clinic Comprehensive Cancer Center.
- 6Memorial Sloan Kettering Cancer Center.
Zitieren
APA
Shah, N. P., Bhatia, R., Altman, J. K., Amaya, M., Begna, K. H., Berman, E., Chan, O., Clements, J., Collins, R. H., Curtin, P. T., DeAngelo, D. J., Drazer, M., Maness, L., Metheny, L., Mohan, S., Moore, J. O., Oehler, V., Pratz, K., Pusic, I., …, & Gregory, K. (2024). Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 22(1), 43-69. https://doi.org/10.6004/jnccn.2024.0007
Vancouver
Shah NP, Bhatia R, Altman JK, Amaya M, Begna KH, Berman E, et al. Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2024;22(1):43-69. doi:10.6004/jnccn.2024.0007
BibTeX
@article{Shah2024,
author = {Shah, Neil P and Bhatia, Ravi and Altman, Jessica K and Amaya, Maria and Begna, Kebede H and Berman, Ellin and Chan, Onyee and Clements, Joan and Collins, Robert H and Curtin, Peter T and DeAngelo, Daniel J and Drazer, Michael and Maness, Lori and Metheny, Leland and Mohan, Sanjay and Moore, Joseph O and Oehler, Vivian and Pratz, Keith and Pusic, Iskra and Rose, Michal G and Shomali, William and Smith, B Douglas and Styler, Michael and Talpaz, Moshe and Tanaka, Tiffany N and Tantravahi, Srinivas and Thompson, James and Tsai, Steven and Vaughn, Jennifer and Welborn, Jeanna and Yang, David T and Sundar, Hema and Gregory, Kristina},
title = {Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology},
journal = {Journal of the National Comprehensive Cancer Network},
year = {2024},
volume = {22},
number = {1},
pages = {43--69},
doi = {10.6004/jnccn.2024.0007}
}
EUVIMED